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Recent literature indicates a potential importance of the gut microbiota for immune-
mediated diseases. For instance, decreased diversity of commensals or an outgrowth of
some bacterial strains, referred to as gut dysbiosis, was recently linked to hypertension,
colitis, lupus, rheumatoid arthritis, and multiple sclerosis (MS). Studies in experimental
autoimmune encephalomyelitis (EAE) as pivotal animal model of MS revealed a poten-
tial importance of microbial metabolites, including short-chain fatty acids or tryptophan
metabolites. Both metabolites may influence the disease by modulation of the immune
system, mainly by inducing Treg. These studies prompted researchers to investigate the
contribution of the gut microbiota and microbial metabolites in the pathogenesis of MS.
This review summarizes recent findings on the gut microbiota in MS patients and dis-
cusses the potential mechanisms how microbial metabolites may affect neuroinflamma-
tion.Many of these studies have been performed in the EAEmodel andwere later reversely
translated to humans.We also give a short summary on dietary high-salt effects onmicro-
biota components and discuss the potential relevance of high-salt as a risk factor in MS.
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Introduction
Humans are colonized by millions of microorganisms, which
behave as symbionts, commensals, or pathogens. This complexity
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of microorganisms, collectively called the microbiota, is mainly
localized in the gastrointestinal tract [1]. The number of bacterial
cells at least equals that of human cells within the human body
[2], suggesting an enormous impact of the microbiota on host
physiology. Indeed, intestinal bacteria may exert major effects on
the host, especially via interaction with the immune system. The
intestine harbors pivotal cell types and mediators of the innate
as well as the adaptive immune system, thus representing an
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important immune organ in the body. The lamina propria and
the mesenteric lymph nodes are populated by DCs, macrophages,
and lymphocytes [3]. Communication between the microbiota
and these lymphocyte populations is enabled by the presentation
of cell wall components via APCs, by soluble factors (microbial
metabolites), or by the stimulation and modulation of intestinal
epithelial cells. The gut microbiota is highly dynamic and can
be influenced by the genetic environment of the host and exter-
nal factors, especially dietary intake. An established microbial
imbalance is termed dysbiosis, a state that is related to altered
metabolite production. Gut dysbiosis has been linked to local and
systemic inflammation, obesity [4], type 2 diabetes [5], inflam-
matory bowel disease [6], hypertension [7, 8], and also multiple
sclerosis (MS) [9, 10]. One integral dietary component that has
recently been linked to changes in microbiota composition and
function is dietary salt (sodium chloride). According to World
Health Organization, most adults from the Western hemisphere
consume twice the recommended maximum of salt per day
[11]. This increased salt intake was shown to promote local
and systemic tissue inflammation and impair intestinal anatomy
in both human and animal settings. A large number of studies
demonstrate that extracellular high-salt concentrations modulate
immune homeostasis by affecting various cell types (reviewed
in [12]). In brief, high-salt concentrations favor the activation of
pro-inflammatory M1 macrophages [13, 14] and T helper (Th)
17 cells [15, 16], whereas the induction of anti-inflammatory
M2 macrophages [17] and the suppressive capacity of regulatory
T cells (Treg) [18] are reduced. Thus, high-salt concentrations
in the cellular environment shift the immune balance toward a
pro-inflammatory state, which provides a potential explanation
for the disease-promoting effect of diets rich in salt, which has
been observed in various models of immune-mediated diseases
[19]. In addition to these direct effects, recent research identified
the gut and the gut microbiota as one integral mediator involved
in the deleterious effects of high-salt conditions on immune cells.
Relevance of microbial changes in MS
The adult microbiota is largely defined by two dominant phy-
lotypes, namely Bacteroidetes and Firmicutes [20]. The ratio of
these very broad taxa tends to remain stable over months or
years, although the composition within these broad phylotypes
differs between healthy individuals. This interindividual variety
may be attributed to age and gender [21], antibiotic intake [22],
and dietary habits [23]. Moreover, the immune system has a
profound effect on the microbiota composition, and vice versa,
the gut microbiota shapes the immune system [24]. This finding
tempted many research to investigate the potential contribution
of gut microorganisms in immune-mediated diseases.
MS is an autoimmune disease affecting the central ner-
vous system (CNS). After peripheral activation, immune cells
enter the CNS, leading to neuroinflammatory processes, myelin
degradation, and axonal loss. Despite growing interest in the
role of B cells, T cells are assumed as main pathogenic drivers.
Consequently, MS pathology is characterized by increased fre-
quencies of Th17 and Th1 cells, but functionally impaired Treg
cells [25]. Pivotal studies in experimental models first suggested
that the gut microbiota contributes to MS. EAE is one of the
most commonly used animal model of MS. It can be induced by
active immunization with myelin peptides or passive transfer of
myelin-reactive T cells [26]. Oral antibiotic treatment before EAE
induction reduced EAE development in mice, coinciding with an
alteration of the gut bacteria composition [27, 28]. The potential
relevance of gut microorganisms in EAE was later confirmed in
germ-free mice lacking intestinal microbiota. Germ-free mice
are protected from EAE development, which could be linked to
reduced Th1 and Th17 responses [29, 30]. The transfer of spe-
cific bacteria into germ-free mice, such as segmented filamentous
bacteria, restored the susceptibility to EAE induction by inducing
Th17 cells in the intestine [30]. In contrast, mononcolonization
with Bacteroides fragilis after oral antibiotic treatment prevented
the onset of EAE by increased generation of interleukin (IL)-10
producing Treg cells [31]. These data prompted researchers to
perform sequencing analyses of 16S ribosomal DNA isolated from
fecal samples obtained from MS patients compared to healthy
donors. These studies revealed that the overall diversity of the
gut microbiota in MS patients is comparable to that observed
in healthy controls. However, the relative abundance of specific
bacteria was significantly altered. MS patients show an enrich-
ment of Clostridium [32], Pseudomonas, Mycoplana, Haemophilus,
Blautia, and Dorea genera [33] as well as Methanobrevibacter
and Akkermansia [9, 34]. Other studies identified a decreased
occurrence of species belonging to Clostridia clusters XIVa and
IV and Bacteroidetes [10]. So far, most of these studies were
performed in patients with relapsing remitting MS. In contrast,
researchers just started to investigate the importance of micro-
biota changes in patients with different stages of MS [35, 36].
These studies revealed differences in the relative abundance
of rare phyla in primary progressive MS patients compared to
healthy controls [35]. Secondary progressive MS patients show a
relative increase of the Streptococcuss genus, which was suggested
to correlate with increased oxidative stress in the gut [36]. In
contrast, the gut microbiota of relapsing remitting MS patients
was characterized by decreased abundance of short-chain fatty
acid (SCFA) producing bacteria compared to healthy controls
[36], confirming previous studies that demonstrated a relative
contribution of microbial SCFAs during neuroinflammation
[37]. Potential mechanisms of gut microbiota alterations in MS
patients have been studied in the EAE model that might in part
be transferred back to the human disease.
Potential mechanism of microbial changes
obtained in animal models of MS
Standard approaches for investigation of potential contributions
of disease-relevant bacterial strains to MS pathogenesis are
bacterial monocolonization or stool transfer experiments in mice
subjected to EAE. In one such study, transplantation of human gut
© 2020 The Authors. European Journal of Immunology published by
Wiley-VCH GmbH
www.eji-journal.eu
Eur. J. Immunol. 2020. 50: 1863–1870 HIGHLIGHTS 1865
Figure 1. Contribution of the gut microbiota and microbiota metabolites during neuroinflammation in mice.
The transfer of single bacterial strains into germ-free or antibiotic-treated mice can either induce a pro-inflammatory or anti-inflammatory state
in the gut during neuroinflammation. Left: Bacterial strains that were shown to be increased in MS patients enhance the differentiation of Th1
and Th17 cells in the gut, whereas regulatory immune cells such as Treg cells are decreased. These bacterial strains include segmented filamen-
tous bacteria (SFB), Akkermansia muciniphila and Acinetobacter calcoaceticus that might induce alterations in immune cell composition via increased
reactive oxygen species (ROS) production, mucin degradation or the activation of DCs. Right: In contrast, bacterial strains that were shown to be
reduced in MS patients induce an anti-inflammatory phenotype in the gut when transferred into germ-free or antibiotic-treated mice. Metabolite
analysis revealed an increased concentration of short-chain fatty acids (SCFAs), tryptophan metabolites or polysaccharide-A (PSA), thus shifting
the immune cell composition towards increased Treg cell frequencies. SCFAs can also directly modulate the blood-brain barrier (BBB) or CNS resi-
dent cells such as microglia. Moreover, tryptophan metabolites were shown to affect astrocytes via aryl hydrocarbon receptor (AHR) signaling, thus
ameliorating neuroinflammation.
microbial organisms from MS-affected monozygotic twins into
the spontaneous relapsing-remitting EAE model resulted in an
increased frequency of spontaneous clinical signs compared to the
transfer of stool samples from healthy twins [38]. Immunological
analysis of these mice revealed a decreased IL-10 production in
mice colonized with the stool from MS patients, probably linking
decreased anti-inflammatory cells to an increased EAE incidence
[38]. Similar results could be obtained by the transfer of single
microorganisms to germ-free or antibiotic-treated mice (Fig. 1).
The transfer of Parabacteroides distasonis (found to be decreased
in MS patients) increased the differentiation of CD4+IL-10+
cells, whereas bacteria that were increased in MS patients (Akker-
mansia muciniphila and Acinetobacter calcoaceticus) enhanced
the differentiation of pro-inflammatory Th1 cells in mice [34].
Further in vitro experiments in human peripheral blood mononu-
clear cells (PBMCs) confirmed the induction of anti-inflammatory
IL-10 secreting CD4+CD25+ T cells by P. distasonis, whereas the
stimulation of PBMCs with A. muciniphila and A. calcoaceticus
increased pro-inflammatory immune responses [34]. The modu-
lation of IL-10 producing Treg cells was also observed after the
reconstitution of EAE mice with Prevotella histicola, a bacterium
that is significantly reduced in stool samples of MS patients [39,
40]. These data indicate that differences in specific gut bacteria
are functionally associated with a shift toward a pro-inflammatory
T-cell profile while decreasing regulatory immune cells in MS.
This effect is mainly attributed to the SCFAs butyrate, propionate,
and acetate, microbial fermentation products of dietary fiber.
SCFAs may directly affect T-cell differentiation. In contrast,
propionate treatment decreases the differentiation of Th17 cells
[41], whereas treatment with butyrate and propionate increases
the differentiation of Treg cells and enhances their suppressive
capacity [41–43]. Other studies identified a potential importance
of microbial SCFA on blood–brain barrier (BBB) integrity [44].
Germ-free mice showed a reduced expression of tight-junction
proteins and an increased BBB permeability compared to mice
with a normal gut microbiota. Interestingly, BBB permeability
could be decreased by the colonization with SCFA-producing
bacteria or direct treatment with butyrate [44]. Other effects of
SCFAs have been observed on microglial cells [45]. Germ-free
mice displayed altered microglia maturation, differentiation, and
function, which could be restored by microbiota recolonization
or SCFA treatment. In addition to SCFAs, polysaccharide A
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Figure 2. Potential mechanism of high-salt induced EAE exacerbation via modulations in the gut.
Under normal salt conditions, the gut commensal Lactobacillus produces tryptophan metabolites that can block Th17 cell differentiation in the
gut (left). After high-salt intake, some bacterial species are increased in mice, including Lachnospiraceae, Ruminococcus and Prevtolla spp., whereas
Lactobacillus are depleted in the gut microbiota. Decreased Lactobacillus was shown to coincide with increased Th17 cell frequencies in the gut,
probably mediated by decreased production of tryptophan metabolites. Moreover, high-salt concentrations reduce short-chain fatty acid (SCFA)
concentrations in the gut, thereby decreasing Treg cell differentiation. The shift toward pro-inflammatory Th17 cells in the gut due to high-salt-
induced microbiota changes was shown to exacerbate EAE, the animal model of MS.
(PSA) produced by B. fragilis may induce the differentiation
of IL-10-producing Treg cells [46] and PSA treatment during
EAE can protect mice from disease development [31]. Moreover,
tryptophan metabolites may modulate T-cell subsets by either
promoting Th1 and Th17 differentiation or by the induction of
Treg cells (reviewed in [47]). Interestingly, tryptophan metabo-
lites can be produced by different strains from the bacteria
genera Lactobacillus [48], and Lactobacilli were recently shown
to ameliorate EAE by reducing Th1 and Th17 cells [49–51]. In
addition, neurotransmitters such as gamma amino butyric acid,
serotonin, or norepinephrine can be produced by gut microorgan-
isms [52–54] and may have a potential role in MS pathogenesis
[55]. Yet, the here discussed gut bacterial metabolites represent a
small fraction of metabolites that were shown to influence animal
models of MS. Besides SCFAs, tryptophan metabolites, PSA or
neurotransmitters, lactic acid, poly-γ-glutamic acid, or cell wall
components such as peptidoglycan may also be considered as
potential contributors in MS pathology [56–59].
Modulations of the gut microbiota and its
metabolites by high-salt concentrations
Dietary factors can disturb and alter the microbiota composition
and function, including the production of microbial metabolites.
This is not surprising, assuming that dietary components first pass
the gastrointestinal tract before being absorbed and distributed to
tissues [60]. Several studies identified alterations of the microbial
composition by high-salt ingestion. In humans and mice, high-
salt intake was associated with changes in the gut microbiome
reflecting an increased ratio of Firmicutes to Bacteroidetes [61]
(Fig. 2). More in detail, bacteria enriched by high-salt primarily
belong to the family Lachnospiraceae [61] or Prevotella spp. in
mice and humans [62]. Prevotella have been associated with
chronic inflammation in rheumatoid arthritis [63] but had a
positive effect in the animal model of MS [40]. Yet, Prevotella
comprise a large number of species, a fact that probably explains
these contradictory data. In contrast, elevated salt intake was
associated with a reduction of Lactobacillus [50, 61], a genus
that was beneficially linked to effects in colitis [64], salt-induced
hypertension [50], and neuroinflammation [49–51]. During neu-
roinflammation, the high-salt-induced depletion of Lactobacillus
was paralleled by the induction of Th17 cells in the gut and
spleen, coinciding with deteriorating EAE symptoms [50]. These
data confirmed previous studies, indicating that high-salt concen-
trations may affect neuroinflammation via Th17 cell induction
[16, 65]. Interestingly, oral administration of Lactobacilli during
EAE prevented the salt-induced aggravation of EAE and decreased
Th17 cell differentiation in the gut [50]. Independent of high-salt
concentrations, recently published studies confirmed the benefi-
cial effect of Lactobacillus treatment during EAE [49, 51]. One
possible mechanism of high-salt-induced Th17 differentiation via
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modulation of the gut microbiota may be the high-salt-induced
alteration of microbial metabolites. High-salt intake in mice was
paralleled by reduced concentrations of the fecal tryptophan
metabolite indole-3-lactic acid [50], a tryptophan metabolite
produced by Lactobacilli [48, 50]. Supplementation of indoles
during EAE reduced CNS inflammation, probably by activating
aryl hydrocarbon receptor signaling in astrocytes [66]. Moreover,
indole-3-lactic acid inhibited Th17 cell polarization in vitro and
may thus link the high-salt diet-induced suppression of Lacto-
bacillus to the induction of Th17 cells in EAE [50]. In addition to
decreased tryptophan metabolite concentrations, high-salt intake
in mice also decreased the concentration of SCFAs [64, 67].
Recent studies have shown that SCFAs exert beneficial effects in
EAE mice [41, 68]. The administration of the SCFA propionate
during EAE ameliorated disease symptoms by increasing Treg
cell frequencies in the small intestine, thus leading to a more
anti-inflammatory environment in the gut [41]. This beneficial
effect on EAE severity has also been demonstrated for high-
fiber intake, resulting in increased SCFA concentrations in the
gut [68].
Clinical relevance of microbial restoration in
patients with MS
It is controversially discussed whether high-salt intake might
represent a risk factor in MS. Many studies revealed a posi-
tive correlation of high-salt intake and EAE severity [16, 50,
65, 69–71]. However, others identified that high-salt-mediated
aggravation of EAE is sex and gene dependent in mice [72]. One
observational study in humans found higher relapse rates and
increased numbers of MRI lesions in two cohorts of relapsing
remitting MS patients with high-salt intake [73]. In contrast,
another study revealed no effects of high-salt consumption on
the conversion from clinically isolated syndrome to MS [74].
Moreover, two studies in pediatric MS found that high-salt
consumption does neither increase the risk of MS development
nor affect the time to relapse [75, 76]. Yet, this limited number
of studies in different forms of MS and partly different methods
for the quantification of salt intake are insufficient to confirm
or exclude any high-salt effects in MS. Considering the number
of studies demonstrating salt effects on immune cell subsets
[12] and immune-related diseases [19], it seems likely that
high-salt intake may represent a risk factor for autoimmunity.
Yet, further studies in MS patients will be needed to proof this
assumption. However, there are newly published studies showing
that reconstitution of high-salt altered microbiota metabolites
during MS can impact disease progression. Indicating a poten-
tial relevance of high-salt-induced depletion of Lactobacilli in
humans, we showed that a short-term high-salt challenge in
healthy humans affects the survival of intestinal Lactobacillus,
alongside increased frequencies of Th17 cells in the blood [50].
Yet, it is unclear whether Lactobacillus-mediated high-salt effects
can be transferred from the EAE model to MS. However, a poten-
tial importance has been suggested in an earlier study, showing
that Lactobacillus spp. abundance is decreased in patients with
relapsing–remitting MS [33]. Moreover, a pilot study in humans
demonstrated the relevance of probiotics as immunomodulatory
agents in MS patients and healthy controls [77]. Administration
of a probiotic cocktail of eight bacteria containing Lactobacillus
spp. induced changes in the gut microbiota composition that
were associated with anti-inflammatory immune responses and
decreased frequencies of intermediate monocytes in the periphery
[77, 78]. The probiotic treatment restored gut bacteria that were
depleted in MS patients, including Lactobacillus, and decreased
the frequency of inflammatory monocytes, indicating a potential
benefit of probiotic treatment as add-on to established MS ther-
apies. Further clinical trials are necessary to prove this concept.
A further benefit in MS therapy has been observed for SCFAs.
Analysis of human gut microbial metabolites revealed an altered
SCFA concentration in MS patients compared to healthy con-
trols [43, 79]. Based on our insights obtained in EAE mice,
we recently investigated the impact of propionate administra-
tion in MS patients and healthy controls [43]. In a proof-of-
concept study, propionate was supplemented to treatment naïve
MS patients or as add-on to their immunotherapy for 2 weeks. In
both settings, propionate intake resulted in a significant increase
of Treg cells, while Th1 and Th17 cells significantly decreased.
Moreover, retrospective analyses of a long-time propionate intake
revealed a reduced annual relapse rate and stabilization of disabil-
ity [43]. Interestingly, the Treg inducing effect of propionate was
connected to the gut microbiota. In a sophisticated gut explant
model, intestinal colonization with microbiome derived from MS
patients who received propionate compared with pre-therapy
microbiome led to an upregulation of gene expression patterns
associated with Treg development [43]. These data place pro-
pionate as a potential add-on therapy to currently existing MS
drugs.
Summary and conclusion
A diet containing high amounts of salt results in alterations of
gut microbiota composition and function that may induce a pro-
inflammatory immune phenotype. In particular, a suppression of
Lactobacillus spp. may be a contributing factor. On a functional
level, such salt-induced alterations to the community may result
in a reduced intestinal production of SCFAs and indole metabo-
lites. The direct supplementation of metabolites of bacterial ori-
gin, such as propionate, may circumvent gut dysbiosis and exert
beneficial effects by increasing regulatory immune mechanisms,
as shown in MS. Thus, exploiting microbiota-mediated mech-
anisms, either by re-shaping the gut microbiome or by direct
administration of bacterial metabolites, is a promising approach
to reverse salt-induced pathomechanisms. The use of prebiotics
(e.g. indigestible carbohydrates), probiotics (targeted administra-
tion of live bacteria), or postbiotics (specific metabolites of bacte-
rial origin) may therefore be a novel therapeutic avenue to restore
immune cell homeostasis in immune-mediated diseases such as
MS.
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